2014 AHA/acc guideline for the management of patients with Non-ST-Elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Ezra A. Amsterdam, Nanette K. Wenger, Ralph G. Brindis, Donald E. Casey, Theodore G. Ganiats, David R. Holmes, Allan S. Jaffe, Hani Jneid, Rosemary F. Kelly, Michael C. Kontos, Glenn N. Levine, Philip R. Liebson, Debabrata Mukherjee, Eric D. Peterson, Marc S. Sabatine, Richard W. Smalling, Susan J. Zieman

Research output: Contribution to journalArticlepeer-review

1431 Scopus citations
Original languageEnglish (US)
Pages (from-to)e139-e228
JournalJournal of the American College of Cardiology
Volume64
Issue number24
DOIs
StatePublished - Dec 23 2014

Bibliographical note

Funding Information:
American College of Cardiology Patrick O’Gara, MD, FACC, President Shalom Jacobovitz, Chief Executive Officer William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, and Quality Amelia Scholtz, PhD, Publications Manager, Clinical Policy and Pathways American College of Cardiology/American Heart Association Lisa Bradfield, CAE, Director, Science and Clinical Policy Emily Cottrell, MA, Quality Assurance Specialist, Science and Clinical Policy Alexa Papaila, Specialist, Science and Clinical Policy American Heart Association Elliot Antman, MD, FAHA, President Nancy Brown, Chief Executive Officer Rose Marie Robertson, MD, FAHA, Chief Science Officer Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations Marco Di Buono, PhD, Vice President, Science, Research, and Professional Education, Office of Science Operations Jody Hundley, Production Manager, Scientific Publications, Office of Science Operations Appendix 1

Funding Information:
Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section ∗ Ezra A. Amsterdam (Chair) University of California (Davis) Medical Center, Division of Cardiology—Professor None None None None None None None Nanette K. Wenger (Vice Chair) Emory University, School of Medicine—Professor of Medicine (Cardiology) • Abbott • Amgen • AstraZeneca • Gilead Sciences † • Janssen Pharmaceuticals • Medtronic • Merck • Pfizer None None • Abbott † • Eli Lilly † • Gilead Sciences † • Merck • Pfizer † None None All sections except 3.1.1 , 3.4 , 5.2 , 6.3.1 , 6.3.2 , 6.3.6 , 7.5 , 7.6 , 7.8 , and 8 . Ralph G. Brindis University of California, San FranciscoDepartment of Medicine and the Phillip R. Lee Institute for Health Policy Studies—Clinical Professor of Medicine None • Volcano None None None None None Donald E. Casey, Jr Atlantic Health—Vice President of Health and Chief Medical Officer None None None None None None None Theodore G. Ganiats University of California, San Diego School of Medicine—Executive Director of Health Services Research Center None None None None None None None David R. Holmes, Jr Mayo Clinic—Consultant, Cardiovascular Diseases None None None None None None None Allan S. Jaffe Mayo Clinic, Cardiovascular Division—Professor of Medicine • Abbott • Alere • Amgen • Beckman-Coulter • Critical Diagnostics • ET Healthcare • Ortho Clinical Diagnostic • Radiometer † • Roche ‡ • Thermo-Fisher ‡ • Trinity None None None None None All sections except 3.1 , 3.1.1 , 3.3 , 4.1.2.1-4.1.2.3 , 4.2 , 4.3.1 , 4.3.2 , 4.5 , 5.1 , 5.2 , 6.2.1 , 6.3.1 , 6.3.3 , 6.3.6 , 7.2.2 , 7.5 , 7.6 , and 8 . Hani Jneid Baylor College of Medicine—The Michael E. DeBakey VA Medical Center—Assistant Professor of Medicine None None None None None None None Rosemary F. Kelly University of Minnesota—Professor of Surgery; VA Medical Center—Chief, Cardiothoracic Surgery None None None None None None None Michael C. Kontos Virginia Commonwealth University, Pauley Heart Center—Medical Director, Coronary Intensive Care Unit, and Associate Professor, Internal Medicine • Astellas • General Electric • Ikaria • Prevencio • Sanofi-aventis • Wellpoint/ Anthem • Astellas • AstraZeneca None None • Astellas • Eli Lilly ‡ • Merck ‡ • Novartis ‡ None All sections Glenn N. Levine Baylor College of Medicine—Professor of Medicine; Director, Cardiac Care Unit None None None None None None None Philip R. Liebson Rush University Medical Center—McMullan-Eybel Chair of Excellence in Clinical Cardiology and Professor of Medicine and Preventive Medicine None None None None None None None Debabrata Mukherjee Texas Tech University Health Sciences Center—Chief, Cardiovascular Medicine None None None None None None None Eric D. Peterson Duke University Medical Center—Fred Cobb, MD, Distinguished Professor of Medicine; Duke Clinical Research Institute—Director • Boehringer Ingelheim • Genentech • Janssen Pharmaceuticals • Johnson & Johnson • Merck None None • Eli Lilly † • Johnson & Johnson † • Janssen Pharmaceuticals † DCRI has numerous grants and contracts sponsored by industry that are relevant to the content of this CPG. Dr. Peterson participated in discussions but recused himself from writing or voting, in accordance with ACC/AHA policy. See comprehensive RWI table for a complete list of companies pertaining to this organization. None All sections Marc S. Sabatine Brigham and Women's Hospital, Chairman—TIMI Study Group, Division of Cardiovascular Medicine; Harvard Medical School—Professor of Medicine • Amgen • AstraZeneca • Bristol-Myers Squibb • Merck • Pfizer • Sanofi-aventis None None • Abbott Laboratories † • Amgen † • AstraZeneca † • Bristol-Myers Squibb † • BRAHMS † • Critical Diagnostics † • Daiichi-Sankyo † • Genzyme † • GlaxoSmithKline † • Nanosphere † • Roche Diagnostics † • Sanofi-aventis † • Takeda † • AstraZeneca † • Daiichi-Sankyo † • Gilead † • Johnson & Johnson † • Merck † • Proventys † • Siemens † • Singulex † None All sections except 3.1.1 , 5.2 , 6.3.1 , 6.3.2 , 7.5 , 7.8 , and 8 . Richard W. Smalling University of Texas, Health Science Center at Houston—Professor and Director of Interventional Cardiovascular Medicine; James D. Woods Distinguished Chair in Cardiovascular Medicine • Gilead • Maquet None None • Cordis • E-valve Abbott Vascular • Edwards Lifesciences • Gilead • Maquet Datascope • Cordis † • E-valve † None All sections except 3.1 , 3.1.1 , 3.3 , 3.4 , 3.5.1 , 4.1.2.1-4.1.2.3 , 4.2 , 4.3.1 , 4.3.2 , 5.2 , 6.2.1 , 6.3.1 , 6.3.2 , 6.3.3 , 6.3.6 , 7.2.2 , 7.5 , 7.8 , and 8 . Susan J. Zieman National Institute on Aging/NIH, Geriatrics Branch, Division of Geriatrics and Clinical Gerontology—Medical Officer None None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the GWC during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document ; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document , or makes a competing drug or device addressed in the document ; or c) the person or a member of the person’s household , has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document . ACC indicates American College of Cardiology, AHA, American Heart Association, BMS, Bristol-Myers Squibb; CPG, clinical practice guideline; DCRI, Duke Clinical Research Institute; NIH, National Institutes of Health; NYU, New York University; RWI, relationships with industry and other entities; TIMI, Thrombolysis In Myocardial Infarction; and VA, Veterans Affairs. ∗ Writing members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. † Significant relationship. ‡ No financial benefit. Appendix 2

Cite this